Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

By Robin Sawka, BioCentury Staff | Jul 22, 2020 | 1:07 AM GMT

David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO on an interim basis. Meeker was president and CEO of KSQ Therapeutics Inc., and